Effectiveness of the combination of memantine plus vitamin d on cognition in patients with Alzheimer disease: A pre-post pilot study

Cognitive and Behavioral Neurology

Volumn 25, Issue 3, 2012, Pages 121-127

  Annweiler, Cédric ^a,b,c   Herrmann, François R ^d   Fantino, Bruno ^b,c   Brugg, Bernard ^e   Beauchet, Olivier ^a,b,c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b University Memory Clinic   (France)

^c UNIVERSITÉ D'ANGERS   (France)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Alzheimer disease; memantine; older adults; pre post study; vitamin D

Indexed keywords

MEMANTINE; VITAMIN D;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PILOT STUDY; PRETEST POSTTEST CONTROL GROUP DESIGN; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEMANTINE; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PILOT PROJECTS; TREATMENT OUTCOME; VITAMIN D;

EID: 84866425328     PISSN: 15433633     EISSN: 15370887     Source Type: Journal    
DOI: 10.1097/WNN.0b013e31826df647     Document Type: Article

References (60)

1. Abbott A. Dementia: a problem for our age. Nature. 2011;475: S2-S4.
2. Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet. 2011;377:1019-1031.
3. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329-344.
4. Rigaux N. Autonomy and dementia. Geriatr Psychol Neuropsychiatr Vieil. 2011;9:107-115.
5. Herrmann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother. 2011;12:787-800.
6. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;CD003154.
7. Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer's disease. Drugs. 2006;66:1515-1534.
8. Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834-1839.
9. Van Gool WA. Het effect van rivastigmine bij de ziekte van Alzheimer. Houdt rivastigmine het alledaagse gewoon? [The effect of rivastigmine in Alzheimer's disease. Does rivastigmine keep everyday life ordinary?]. Geneesmiddelenbulletin. 2000;34:17-22.
10. Schrag A, Schott JM, Alzheimer's Disease Neuroimaging Initiative. What is the clinically relevant change in ADAS-cog score? J Neurol Neurosurg Psychiatry. 2012;83:171-173.
11. Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008;51:347-372.
12. Liu RT, Lu QJ. Progress in the research on multi-target-directed drugs against Alzheimer's disease. Yao Xue Xue Bao. 2009;44: 258-263.
13. Annweiler C, Beauchet O. Possibility of a new anti-Alzheimer pharmaceutical composition combining memantine and vitamin D. Drugs Aging. 2012;29:81-91.
14. Kalueff AV, Tuohimaa P. Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr Opin Clin Nutr Metab Care. 2007;10:12-19.
15. Annweiler C, Schott AM, Berrut G, et al. Vitamin D and ageing: neurological issues. Neuropsychobiology. 2010;62:139-150.
16. Garcion E, Wion-Barbot N, Montero-Menei CN, et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002;13:100-105.
17. Dickens AP, Lang IA, Langa KM, et al. Vitamin D, cognitive dysfunction and dementia in older adults. CNS Drugs. 2011;25: 629-639.
18. Annweiler C, Beauchet O. Vitamin D-mentia: randomized clinical trials should be the next step. Neuroepidemiology. 2011;37:249-258.
19. Annweiler C, Allali G, Allain P, et al. Vitamin D and cognitive performance in adults: a systematic review. Eur J Neurol. 2009; 16:1083-1089.
20. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
22. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
23. Barrett PH, Okawa G, Bowman J. Evidence-based guidelines. Perm J. 2005;9:83-88.
24. Cole MG,McCusker J, Bellavance F, et al. Systematic detection and multidisciplinary care of delirium in older medical inpatients: a randomized trial. CMAJ. 2002;167:753-759.
25. Doggrell SA. Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help? Drugs Aging. 2010;27:239-254.
26. Annweiler C, Souberbielle JC, Schott AM, et al. Vitamin D in the elderly: 5 points to remember. Geriatr Psychol Neuropsychiatr Vieil. 2011;9:259-267.
27. Benhamou CL, Souberbielle JC, Cortet B, et al. Vitamin D in adults: GRIO guidelines. Presse Med. 2011;40:673-682.
28. Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 1995;15:961-973.
29. Bonfoco E, Krainc D, Ankarcrona M, et al. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA. 1995;92:7162-7166.
30. Annweiler C, Schott AM, Allali G, et al. Association of vitamin D deficiency with cognitive impairment in older women: crosssectional study. Neurology. 2010;74:27-32.
31. Annweiler C, Fantino B, Schott AM, et al. Vitamin D insufficiency and mild cognitive impairment: cross-sectional association. Eur J Neurol. 2012;19:1023-1029.
32. Annweiler C, Fantino B, Le Gall D, et al. Severe vitamin D deficiency is associated with advanced-stage dementia in geriatric inpatients. J Am Geriatr Soc. 2011;59:169-171.
33. Buell JS, Dawson-Hughes B, Scott TM, et al. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology. 2010;74:18-26.
34. Etgen T, Sander D, Bickel H, et al. Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. Dement Geriatr Cogn Disord. 2012;33:297-305.
35. Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med. 2010;170:1135-1141.
36. Annweiler C, Rolland Y, Schott AM, et al. Serum vitamin D deficiency as a predictor of incident non-Alzheimer dementias: a 7-year longitudinal study. Dement Geriatr Cogn Disord. 2012;32: 273-278.
37. Annweiler C, Schott AM, Rolland Y, et al. Dietary intake of vitamin D and cognition in older women: a large populationbased study. Neurology. 2010;75:1810-1816.
38. Annweiler C, Rolland Y, Schott AM, et al. Higher vitamin D dietary intake is associated with lower risk of Alzheimer's disease: a 7-year follow-up. J Gerontol A Biol Sci Med Sci. 2012. [Epub April 13, 2012].
39. Moore ME, Piazza A, McCartney Y, et al. Evidence that vitamin D3 reverses age related inflammatory changes in the rat hippocampus. Biochem Soc Trans. 2005;33:573-577.
40. Masoumi A, Goldenson B, Ghirmai S, et al. 1Alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2009;17:703-717.
41. Ito S, Ohtsuki S, Nezu Y, et al. 1a,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-b peptide(1-40) from mouse brain across the blood-brain barrier. Fluids Barriers CNS. 2011;8:20.
42. Yu J, Gattoni-Celli M, Zhu H, et al. Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AbetaPP Transgenic Mice. J Alzheimers Dis. 2011;25:295-307.
43. Brewer LD, Thibault V, Chen KC, et al. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci. 2001;21:98-108.
44. Dursun E, Gezen-Ak D, Yilmazer S. A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid-b and preventing the amyloid-b induced alterations by vitamin D in cortical neurons. J Alzheimers Dis. 2011;23:207-219.
45. Gezen-Ak D, Dursun E, Yilmazer S. The effects of vitamin D receptor silencing on the expression of LVSCC-A1C and LVSCCA1D and release of NGF in cortical neurons. PLoS One. 2011;6:e17553.
46. Ibi M, Sawada H, Nakanishi M, et al. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology. 2001;40:761-771.
47. Brown J, Bianco JI, McGrath JJ, et al. 1,25-dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett. 2003;343:139-143.
48. Stark DT, Bazan NG. Synaptic and extrasynaptic NMDA receptors differentially modulate neuronal cyclooxygenase-2 function, lipid peroxidation, and neuroprotection. J Neurosci. 2011;31:13710-13721.
49. Danysz W, Parsons CG, Mobius HJ, et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's Disease-a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res. 2000;2:85-97.
50. Zajaczkowski W, Frankiewicz T, Parsons CG, et al. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology. 1997;36:961-971.
51. Parsons CG, Stö ffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007;53:699-723.
52. Grecksch G, Ruthrich H, Hö lt V, et al. Transient prenatal vitamin D deficiency is associated with changes of synaptic plasticity in the dentate gyrus in adult rats. Psychoneuroendocrinology. 2009;34: S258-S264.
53. Becker A, Eyles DW, McGrath JJ, et al. Transient prenatal vitamin D deficiency is associated with subtle alterations in learning and memory functions in rats. Behav Brain Res. 2005;161:306-312.
54. Kalyani RR, Stein B, Valiyil R, et al. Vitamin D treatment for the prevention of falls in older adults: systematic review and metaanalysis. J Am Geriatr Soc. 2010;58:1299-1310.
55. Przybelski R, Agrawal S, Krueger D, et al. Rapid correction of low vitamin D status in nursing home residents. Osteoporos Int. 2008;19:1621-1628.
56. Annweiler C, Montero-Odasso M, Schott AM, et al. Fall prevention and vitamin D in the elderly: an overview of the key role of the nonbone effects. J Neuroeng Rehabil. 2010;7:50.
57. Truffinet P, Bordet R, Menard J. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease. Therapie. 2009;64:145-148.
58. Annweiler C, Fantino B, Parot-Schinkel E, et al.Alzheimer'sDisease-Input of vitamin D with mEmantine Assay (AD-IDEA trial): study protocol for a randomized controlled trial. Trials. 2011;12:230.
59. Nowson CA, Margerison C. Vitamin D intake and vitamin D status of Australians. Med J Aust. 2002;177:149-152.
60. Crichton ACS, Kee C, Craven R, et al. A global view on fixed-combination therapy for glaucoma. Ophthalmology Times. March 2007:3-10.